Skip to main content


Pronunciation: Troh-DELL-vee
Generic name: sacituzumab govitecan-hziy
Dosage form: injection for intravenous infusion
Drug class: Miscellaneous antineoplastics

Medically reviewed by Melisa Puckey, BPharm. Last updated on Jul 9, 2024.

What is Trodelvy?

Trodelvy is a targeted chemotherapy medication used to treat types of breast cancer and bladder cancer. Trodelvy may help increase the length of time a patient lives and also how long they live without their cancer progressing. For most of these cancers, few other treatments are available. Trodelvy works by attaching to a protein (Trop-2a) on cancer cells, and then the anticancer medicine is released into the cancer cell, killing it. 

Trodelvy is a targeted antibody-drug conjugate (ADC) with an antibody section that attaches to cancer cells Trop-2 proteins, an anticancer drug that kills the cancer cells, and a linker that connects the antibody to the drug. 

Trodelvy is given as an intravenous infusion for the first dose, which lasts 3 hours, and then for the other doses, it lasts 1 to 2 hours.

Trodelvy for lung cancer is under clinical trial for patients with non-small cell lung cancer (NSCLC) who had failed on chemo and PD-1/L1 therapy, this medicine is not FDA-approved for NSCLC.

Who can use Trodelvy?

Trodelvy (sacituzumab govitecan) is FDA-approved to treat adults with the following cancers that have spread (metastasized) or cannot be removed by surgery:

Trodelvy was first FDA approved on April 22, 2020, under the accelerated approval designation for relapsed or refractory metastatic TNBC, and gained full approval for this indication on April 7, 2021. It was granted accelerated approval for metastatic urothelial cancer on April 13, 2021 (continued approval may be dependent on clinical trials showing a benefit) and full approval for metastatic HR+/HER2- breast cancer on February 3, 2023.

Trodelvy side effects

Common Trodelvy side effects

Common Trodelvy side effects are: 

These common Trodelvy side effects occurred in 25 % or more of patients.

Serious Trodelvy side effects

Trodelvy can cause severe or life-threatening allergic reactions. Get emergency medical help if you have signs of an allergic reaction such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection or within 24 hours afterward. Tell your medical caregivers if you feel dizzy, light-headed, itchy, sweaty, or have a fever, chills, trouble breathing, or swelling in your face or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

This medicine can can cause severe diarrhea. Tell your doctor right away if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.


Serious hypersensitivity and infusion-related reactions, including anaphylaxis, can occur with Trodelvy. Do not receive this infusion if you have had a severe allergic reaction to the active ingredient sacituzumab govitecan-hziy or any of the inactive ingredients in the injection. There is a full list of ingredients at the bottom of this document.

Diarrhea (Severe): If you have diarrhea, you should be given fluid and electrolytes as needed. At the onset of diarrhea, you will be evaluated for infectious causes, and if negative, you will be promptly given a diarrhea medicine (loperamide). If severe diarrhea occurs, Trodelvy will be stopped until diarrhea has resolved to ≤ Grade 1, and subsequent doses will be reduced. 

Neutropenia (severe or life-threatening). Neutropenia is a low level of neutrophils, a type of white blood cell. If your absolute neutrophil count is below 1500/mm3 or you have neutropenic fever, your Trodelvy treatment will be stopped. Your blood cell counts will be monitored periodically during treatment. You may be given granulocyte colony-stimulating factor (G-CSF) to help your white cell levels recover. Antiinfective treatment will be given without delay if you have febrile neutropenia. 

Nausea and vomiting. This medicine may cause nausea and vomiting, which can be severe. Your healthcare provider should prescribe antiemetic preventive treatment and withhold Trodelvy for patients with Grade 3 nausea or Grade 3-4 vomiting at the time of treatment.

Reduced UGT1A1 activity. Patients with reduced UGT1A1 activity are at increased risk of side effects of Trodelvy, such as low blood cell counts such as neutropenia (low levels of neutrophils – a type of white blood cell), febrile neutropenia, and anemia (low levels red blood cells).

Fetal harm. Trodelvy can cause fetal harm. Women of childbearing potential should use adequate contraception during treatment.

It is not known if Trodelvy is safe and effective in people with moderate or severe liver problems or in children.

Before taking this medicine

You should not be treated with Trodelvy if you have ever had a severe allergic reaction to it.

Tell your doctor if you have ever had:


Trodelvy can harm an unborn baby if the mother or the father is using it.


Do not breastfeed while using this medicine, and for at least 1 month after your last dose.

How is Trodelvy given?

Your healthcare provider will give Trodelvy into your vein through an intravenous (IV) line, the infusion will initially be given over 3 hours. If you tolerate the first dose well, future doses may be given over 1 to 2 hours.

This medicine commonly causes diarrhea. Severe diarrhea can lead to dehydration, which may require medical treatment. Tell your doctor right away the first time you have diarrhea while receiving this medicine.

You may get infections more easily, even serious or fatal infections. You may need frequent medical tests, and your cancer treatments may be delayed based on the results.

Your doctor will determine how long to treat you with this medicine.

Trodelvy Dosing information

Usual Adult Trodelvy Dose for Breast Cancer:

Dose: 10 mg/kg IV once a week on Days 1 and 8 of 21-day treatment cycles
Maximum dose: 10 mg/kg per dose
Duration of therapy: Until disease progression or unacceptable toxicity
For the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of them for metastatic disease.
For the treatment of patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH]-) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Usual Adult Dose for Urothelial Carcinoma:

Dose: 10 mg/kg IV once a week on Days 1 and 8 of 21-day treatment cycles
Maximum dose: 10 mg/kg per dose
Duration of therapy: Until disease progression or unacceptable toxicity
Use: For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.


Do NOT substitute Trodelvy for or use with other drugs containing irinotecan or its active metabolite SN-38.
For intravenous infusion only. Do not administer as an intravenous push or bolus.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your infusion

What happens if I overdose?

In a medical setting an overdose would be treated quickly


Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way Trodelvy works.

This list is not complete. Many other drugs may interact with this medicine including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Click on the link below to check for interactions with this medicine.

Trodelvy Package Insert 

Review the Trodelvy Package Insert for more detailed information about this medicine. Discuss any medical questions you have with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.


Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect them from light until the time of reconstitution. Do not freeze.

Trodelvy is a hazardous drug. Follow applicable special handling and disposal procedures.


Active ingredient: sacituzumab govitecan-hziy

Inactive ingredients: 2-(N-morpholino) ethane sulfonic acid (MES), polysorbate 80, and trehalose dihydrate


Gilead Sciences, Inc.

Popular FAQ

Trodelvy (sacituzumab govitecan-hziy) works by preventing repair of DNA damage in the cancer cell which leads to cell death. It is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. It binds to the antigen Trop-2, a protein found in many cancers, and delivers the anticancer medicine into the tumor. Trop-2 biomarker testing is not required for use with Trodelvy.

Hair loss (alopecia) is one of the most common side effects associated with Trodelvy and may happen soon after you start treatment. In studies in patients being treated for metastatic triple negative breast cancer (mTNBC), alopecia was reported in 47% of patients compared to 16% of patients receiving a single-agent chemotherapy drug (such as eribulin, capecitabine, gemcitabine or vinorelbine).

Trodelvy (sacituzumab govitecan-hziy) is effective for the treatment of triple-negative breast cancers, pre-treated HR+/HER2- metastatic breast cancer, and urothelial cancers in patients with a poor prognosis and limited treatment options who have already been treated with other therapies and who have advanced tumors or tumors that have spread. About 30 percent of patients treated with Trodelvy have a complete or partial response to treatment meaning that their tumors shrink in size. It help some patients gain extra months of life during which time there cancer does not get worse. It also helps some patients live for months longer than they might have otherwise. Three times as many people treated with Trodelvy for pre-treated HR+/HER2- metastatic breast cancer, were progression free at one year versus those treated with chemotherapy (21% versus 7%). Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.